8-K: BiomX Announces Q4 and Full Year 2024 Financial Results, Highlights Progress on Phage Therapy Programs

BiomX reports financial results for Q4 and full year 2024, providing updates on BX211 and BX004 clinical programs and recent financing.

Summary

• BiomX announced its financial results for the fourth quarter and full year ended December 31, 2024.
• The company reported a net loss of $17.7 million for 2024, compared to a net loss of $26.2 million in the prior year.
• Research and development expenses, net were $24.7 million for the year ended December 31, 2024, compared to $16.7 million for the prior year.
• General and administrative expenses were $11.8 million for the year ended December 31, 2024, compared to $8.7 million for the prior year.
• Cash and restricted cash totaled $18.0 million as of December 31, 2024, compared to $15.9 million as of December 31, 2023.
• In February 2025, BiomX completed financings with gross proceeds of approximately $12 million.
• The company expects topline results from the Phase 2 trial of BX211 in diabetic foot osteomyelitis (DFO) by the end of March 2025.
• Topline results from the Phase 2b study of BX004 in cystic fibrosis (CF) are anticipated in the first quarter of 2026.
• BiomX is exploring real-world evidence in people with CF to assess the relationship between Pseudomonas aeruginosa reduction and clinical outcomes, with regulatory discussions expected in the second half of 2025.
• Net cash used in operating activities for the year ended December 31, 2024 was $37 million, compared to $21.3 million for the same period in 2023.
• BiomX estimates its cash, cash equivalents and short-term deposits are sufficient to fund its operations into the first quarter of 2026.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company reported a net loss, it also made progress on its clinical programs and secured additional funding. The manufacturing delays and increased operating expenses are concerning, but the company's cash runway and upcoming clinical trial results provide some optimism.

Positives

• BiomX successfully raised $12 million in gross proceeds in February 2025, extending its cash runway.
• The company is progressing with its BX211 and BX004 clinical programs, with topline results expected in the near future.
• BiomX is actively engaging with regulatory authorities to advance its CF program.
• The net loss for 2024 decreased compared to the prior year, primarily due to the change in the fair value of warrants issued as part of the company's March 2024 financing.

Negatives

• BiomX reported a net loss of $17.7 million for 2024.
• The company experienced manufacturing delays in scaling up materials for the BX004 Phase 2 trial during the fourth quarter of 2024.
• Net cash used in operating activities increased to $37 million for the year ended December 31, 2024, compared to $21.3 million for the same period in 2023.
• Goodwill impairment was $0.8 million for the year ended December 31, 2024, following an impairment of the company's goodwill resulting from the APT acquisition.
• IPR&D impairment was $3.2 million for the year ended December 31, 2024, following the company's quantitative assessment for in process research and development (IPR&D) impairment.
• Long-lived assets impairment was $4.0 million for the year ended December 31, 2024, after evaluating the right-of-use asset and related leasehold improvements following the company's decision to cease the use of the property in Gaithersburg, Maryland and make it available for sublease.

Risks

• Clinical trial results may not be favorable, impacting the development of BX211 and BX004.
• Regulatory discussions may not result in the desired outcomes for the CF program.
• The company's cash resources may not be sufficient to fund its planned activities beyond the first quarter of 2026.
• Competition in the phage therapy space could intensify.
• The company's reliance on collaboration partners could pose risks.
• The company may face challenges in obtaining, maintaining, and enforcing intellectual property rights.

Future Outlook

BiomX expects to report topline results from its Phase 2 trial of BX211 in DFO by the end of March 2025 and topline results from its Phase 2b study of BX004 in CF in the first quarter of 2026. The company also anticipates regulatory discussions regarding its CF program in the second half of 2025. BiomX estimates its cash, cash equivalents and short-term deposits are sufficient to fund its operations into the first quarter of 2026.

Management Comments

• Jonathan Solomon, Chief Executive Officer of BiomX, stated that the company is finalizing the analysis of topline results from the Phase 2 trial of BX211 in DFO, with readout expected by the end of the quarter.
• Jonathan Solomon, Chief Executive Officer of BiomX, stated that the company completed a financing round that generated $12 million in gross proceeds in the first quarter of 2025.
• Jonathan Solomon, Chief Executive Officer of BiomX, stated that the company believes that these resources will enable readout of BX004 Phase 2b topline results, which are anticipated in the first quarter of 2026.

Industry Context

BiomX is operating in the emerging field of phage therapy, which aims to target and destroy harmful bacteria for the treatment of chronic diseases. The company's focus on cystic fibrosis and diabetic foot osteomyelitis addresses significant unmet needs in these areas. The progress of BiomX's clinical programs and regulatory discussions will be closely watched by investors and competitors in the phage therapy space.

Comparison to Industry Standards

• Comparing BiomX's financial performance to other clinical-stage biotech companies is challenging due to the variability in R&D spending and clinical trial timelines.
• However, the company's cash runway into the first quarter of 2026 is a key metric for investors, as it provides visibility into the company's ability to fund its ongoing clinical programs.
• Companies like Armata Pharmaceuticals and Adaptive Phage Therapeutics are also developing phage-based therapies, but their specific clinical targets and development stages differ from BiomX.
• The $36.8 million in non-dilutive funding received for the BX211 Phase 2 trial in DFO is a significant achievement, demonstrating external validation of the program's potential.

Stakeholder Impact

• Shareholders: The financial results and clinical program updates will impact shareholder value.
• Employees: The company's financial stability and clinical progress will affect employee morale and job security.
• Patients: The development of BX211 and BX004 could provide new treatment options for patients with DFO and CF.
• Investors: The company's financial performance and clinical milestones will influence investor confidence and future funding opportunities.

Next Steps

• Report initial topline results from the Phase 2 trial evaluating BX211 for the treatment of DFO by the end of March 2025.
• Continue the Phase 2b trial of BX004 in cystic fibrosis (CF) in patients with chronic pulmonary infections caused by Pseudomonas aeruginosa (P. aeruginosa).
• Hold discussions with the U.S. Food and Drug Administration (FDA) and other regulatory authorities during the second half of 2025, during which the Company intends to present its analyses of real-world evidence and will seek to obtain endorsement that supports potential future regulatory filings.
• Host a conference call and a live audio webcast at a later date to discuss its fourth quarter and full year 2024 financial results, in conjunction with its expected announcement of initial topline results from its Phase 2 trial for subjects with DFO.

Key Dates

Keywords

BiomX, phage therapy, BX211, BX004, cystic fibrosis, diabetic foot osteomyelitis, financial results, clinical trials, regulatory, financing